WCN24-1086 THE EFFICIENCY AND SAFETY OF OBINUTUZUMAB IN THE TREATMENT OF MEMBRANOUS NEPHROPATHY-A RETROSPECTIVE STUDY FROM CHINA

WCN24-1086 THE EFFICIENCY AND SAFETY OF OBINUTUZUMAB IN THE TREATMENT OF MEMBRANOUS NEPHROPATHY-A RETROSPECTIVE STUDY FROM CHINA

Saved in:

Bibliographic Details
Main Authors:	Chen Duqun, Tu Yuanmao, Wang Youliang, Qiu Dandan, Wang Jingjing, Zuo Ke, Cheng Zhen
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924011586
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study
by: Xi Cheng, et al.
Published: (2025-08-01)

Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy
by: Xiaole Su, et al.
Published: (2024-08-01)

Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports
by: Jinmeng Wang, et al.
Published: (2025-04-01)

WCN24-1766 EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY
by: Hiddo J.L. Heerspink, et al.
Published: (2024-04-01)

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
by: Maxime Teisseyre, et al.
Published: (2025-03-01)

WCN24-2238 EXOSTOSIN 1- AND 2- POSITIVE MEMBRANOUS NEPHROPATHY IN CHINESE PATIENTS
by: Hong Cheng, et al.
Published: (2024-04-01)

Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial
by: Li XQ, et al.
Published: (2025-07-01)

WCN24-2320 ANALYSIS OF CLINICOPATHOLOGICAL CHARACTERISTICS OF MEMBRANOUS NEPHROPATHY WITH CONCOMITANT MALIGNANCY AND LITERATURE REVIEW
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN24-2274 CLINICOPATHOLOGICAL AND PROGNOSTIC CHARACTERISTICS OF IDIOPATHIC MEMBRANOUS NEPHROPATHY WITH DUAL ANTIGEN POSITIVITY
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN24-935 NELL-1 Membranous Nephropathy during treatment of Rheumatoid Arthritis with Adalimumab
by: Joselyn Reyes Bahamonde
Published: (2024-04-01)

الاطباء ونشاطاتهم في الامارة المروانيـة (373- 479هـ/ 983- 1086 م)
by: حكيم رمضان سليمان
Published: (2025-06-01)

WCN24-2057 RELAPSE RISK IN PATIENTS WITH MEMBRANOUS NEPHROPATHY AFTER INACTIVATED COVID-19 VACCINATION
by: Hanzhen Zhang, et al.
Published: (2024-04-01)

WCN25-3676 RESULTS FROM THE REGENCY TRIAL ASSESSING EFFICACY AND SAFETY OF OBINUTUZUMAB IN ACTIVE LUPUS NEPHRITIS
by: Brad Rovin, et al.
Published: (2025-02-01)

WCN24-861 SUBCLINICAL RHABDOMYOLYSIS IN MESOAMERICAN NEPHROPATHY
by: Magdalena Madero, et al.
Published: (2024-04-01)

WCN24-2271 WARFARINRELATED NEPHROPATHY IN TWO PATIENTS WITH MECHANICAL VALVES
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN24-2290 A novel approach to induce early remission in high-risk primary membranous nephropathy
by: Vladimir Dobronravov, et al.
Published: (2024-04-01)

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)

WCN24-1092 Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy
by: Kezhi Zhou, et al.
Published: (2024-04-01)

WCN24-2220 A DOUBLE HIT: CASE OF THROMBOTIC MICROANGIOPATHY CONCURRENT WITH MEMBRANOUS NEPHROPATHY IN A PATIENT WITH MYELOPROLIFERATIVE NEOPLASM
by: Yuliya Sharakova
Published: (2024-04-01)

WCN24-186 JAK/STAT EXPRESSION IN PATIENTS WITH IGA NEPHROPATHY
by: Mateus Luvizotto, et al.
Published: (2024-04-01)

WCN24-1475 CLINICAL CHARACTERISTICS OF IGM NEPHROPATHY IN WESTERN MEXICO
by: Alejandro Garcia-Rivera, et al.
Published: (2024-04-01)

WCN24-2606 KIDNEY RE-BIOPSY IN ADULTS WITH IGA NEPHROPATHY
by: Leonel Langellotti, et al.
Published: (2024-04-01)

WCN24-2217 ACUTE PHOSPHATE NEPHROPATHY A CASE REPORT
by: Florencia Pucciariello, et al.
Published: (2024-04-01)

WCN24-559 PROTOCADHERIN FAT1-POSITIVE MEMBRANOUS NEPHROPATHY SECONDARY TO HEMATOPOIETIC STEM-CELL TRANSPLANTATION SUCESSFULLY TREATED WITH RITUXIMAB
by: Hugo Ferreira, et al.
Published: (2024-04-01)

WCN25-3861 Is it Membranous nephropathy in a case of Primary APLA?
by: Rahul Sai Gangula, et al.
Published: (2025-02-01)

WCN24-1459 CRYSTALLINE LIGHT CHAIN NEPHROPATHY WITH COINCIDENTAL CAST NEPHROPATHY AND PROXIMAL TUBULOPATHY: CASE REPORT
by: Johanna Alvarez, et al.
Published: (2024-04-01)

WCN24-1061 ACUTE INTERSTITIAL NEPHROPATHY: CLINICAL-HISTOLOGICAL AND THERAPEUTIC ASPECTS
by: Nermine Ben Achour, et al.
Published: (2024-04-01)

WCN24-679 VANCOMYCIN ASSOCIATED CAST NEPHROPATHY: A CASE REPORT
by: Federico Ezra Dayan, et al.
Published: (2024-04-01)

WCN24-1807 POLYETHYLENE GLYCOL AS AN EXCIPIENT: UNCOMMON CAUSE OF OXALATE NEPHROPATHY
by: Omar Fueyo, et al.
Published: (2024-04-01)

WCN24-995 The Function and Mechanim of Prorenin Receptor (PRR) in Hypertensive Nephropathy
by: Mengjiao Lin, et al.
Published: (2024-04-01)

Obinutuzumab for Relapsing Myeloperoxidase-Antineutrophil Cytoplasmic Autoantibody–Associated Glomerulonephritis
by: Michael Cammarata, et al.
Published: (2025-06-01)

The Occurrence of Richter’s Syndrome during Treatment with Obinutuzumab and Chlorambucil
by: Teng Fong Ng, et al.
Published: (2020-01-01)

WCN25-4122 Rituximab in Primary Membranous Nephropathy- three years outcome
by: Prabjot Kaur Johal, et al.
Published: (2025-02-01)

WCN24-2478 PODOCYTOPATHY ASSOCIATED WITH IGA NEPHROPATHY: IS IT REALLY A PROGNOSTIC FACTOR?
by: BELENGALLEGOS VAZQUEZ, et al.
Published: (2024-04-01)

WCN24-1802 Outcomes in patients with anticoagulant related nephropathy: from bad to worse
by: sergey brodsky, et al.
Published: (2024-04-01)

WCN24-1233 C1Q NEPHROPATHY IN CHILDREN: A CASE SERIES
by: Mayra Lorena Piton, et al.
Published: (2024-04-01)

WCN24-2222 SINGLE TRIGGER, TRIPLE PATTERN. MEMBRANOUS NEPHROPATHY WITH IMMUNE COMPLEX TUBULOINTERSTITIAL NEPHRITIS AND FOCAL NECROTIZING GLOMERULONEPHRITIS: IS IGG4 THE ANSWER?
by: Enrique Iván Rodríguez García, et al.
Published: (2024-04-01)

WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-2270 COMPLEMENT SYSTEM IS OVERACTIVATED IN PATIENTS WITH IGA NEPHROPATHY AFTER COVID-19 INFECTION
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN25-1092 A STUDY OF CLINICOPATHOLOGICAL SPECTRUM AND OUTCOME OF PRIMARY MEMBRANOUS NEPHROPATHY
by: Muzamil ahmad wani, et al.
Published: (2025-02-01)